Document is current

Article History

Received: 22 May 2023

Revised: 10 November 2023

Accepted: 27 November 2023

First Online: 14 December 2023

Competing interests

: D. S. Zebic reports honoraria from Merck. A. Tjokrowidjaja reports research funding (institution) from AZ, support for attending meetings from GSK. K. E. Francis reports funding from BMS, support for attending educational meeting. M. Friedlander reports consulting fees from Novartis, AstraZeneca, MSD, GSK; honoraria from AstraZeneca, GSK, MSD; grants (institution) from AstraZeneca, Novartis, Beigene; participation on a Data Safety Monitoring Board or Advisory Board for AGITG. V. Gebski reports no conflict of interest. A. Lortholary reports participation on Advisory Board for AstraZeneca, MSD Tesaro; honoraria from Clovis Oncology, Roche; congress participation for Novartis, Pfizer, MAD, Lilly, Roche; member of CS3 sein UNICANCER. F. Joly reports participation on Advisory Board for GSK, AstraZeneca, Clovic, Seagen, Janssen, ESAI, Bayer, Viatris, MSD, Ipsen, Amgen, Astellas; honoraria from GSK, Bayer, ESAI, MSD; research funding (personal) from AstraZeneca, GSK; participation member for ASCO, GCIG; congress travel fees from GSK, MSD, ESAI, Ipsen. A. Hasenburg reports honoraria from AstraZeneca, Celgen, GSK, LEO Pharma, MedConcept GmbH, Med update GmbH, Medicultus, Pfizer, Promedicis GmbH, Softconsult, Roche Pharma AG, Streamedup GmbH, Tesaro Bio Germany GmbH; participation on Advisory Board for AstraZeneca, GSK, LEO Pharma, PharmaMar, Promedicis GmbH, Roche Pharma AG, Tesaro Bio Germany GmbH, MSD Sharp&Dohme GmbH. M. Mirza reports participation Data Safety Monitoring Board or Advisory Board for Astra Zeneca, Biocad, GSK, Karyopharm, Merck, Roche, Zailab; honoraria from Astra Zeneca, GSK; research funding (institution) from Apexigen, AstraZeneca, Deciphera (trial chair), GSK, and Ultimovacs; and personal financial interest in Karyopharm (stocks/shares, member of Board of Directors). U. Denison reports no conflict of interest. S. C. Cecere reports honoraria from AstraZeneca, MSD, Pharmamar. A. Ferrero reports honoraria from AstraZeneca, MSD, GlaxoSmithKline, Clovis; participation Data Safety Monitoring Board or Advisory Board for AstraZeneca, MSD. E. Pujade-Lauraine reports honoraria (personal) from AstraZeneca, GSK, Agenus; grants (institution) from AstraZeneca, Merck; participation on Advisory Board or Data Safety Monitoring Board for Incyte, Roche, Pfizer; and is an employee of ARCAGY GINECO research. C.K. Lee reports honoraria from AstraZeneca, Roche, Amgen, GSK, Merck KGA, Novartis, Pfizer, Janssen; grants (institution) from AstraZeneca, Roche, Amgen, Merck KGA; support for attending meetings from AstraZeneca.

: The CALYPSO trial was performed in accordance with principles of good clinical practice, applicable laws and regulations, and the Declaration of Helsinki.

: Written consent was provided by all participants in the CALYPSO trial and other subsequent substudies.